Last reviewed · How we verify
NCT01190943
DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
trial testing Laboratory Biomarker Analysis in Localized Osteosarcoma in 125 participants. Completed.
1 October 2010
Quick facts
| Lead sponsor | Children's Oncology Group |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 6 August 2010 |
| Primary completion | 1 October 2010 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Laboratory Biomarker Analysis — full drug profile →
Conditions studied
- Localized Osteosarcoma — all drugs for Localized Osteosarcoma →
- Metastatic Osteosarcoma — all drugs for Metastatic Osteosarcoma →
- Recurrent Osteosarcoma — all drugs for Recurrent Osteosarcoma →
Sponsor
Children's Oncology Group — full company profile →
Who can join
Eligibility, any sex, with Localized Osteosarcoma or Metastatic Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is studying DNA biomarkers in tissue samples from patients with osteosarcoma. Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.
Llobat L, Gourbault O. · · 2021 · cited 37× · PMID 33922820 · DOI 10.3390/biomedicines9050463 -
Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.
Scotlandi K, Hattinger CM, Pellegrini E, Gambarotti M, et al · · 2020 · cited 25× · PMID 32295254 · DOI 10.3390/cells9040968 -
Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM, Patrizio MP, Luppi S, Serra M. · · 2020 · cited 15× · PMID 32629971 · DOI 10.3390/ijms21134659 -
The Role of MicroRNAs in Uterine Leiomyosarcoma Diagnosis and Treatment.
Psilopatis I, Vrettou K, Kokkali S, Theocharis S. · · 2023 · cited 5× · PMID 37173887 · DOI 10.3390/cancers15092420
Verify or expand the search:
- PubMed search for NCT01190943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Laboratory Biomarker Analysis
Trials testing the same drug.
- NCT04142398 — Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men · withdrawn
- NCT04142385 — Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men · withdrawn
- NCT05558904 — An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cance · Phase 1, PHASE2 · recruiting
- NCT05564650 — Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome · Phase 1 · active not recruiting
- NCT05396859 — Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia · Phase 1 · active not recruiting
Other recruiting trials for Localized Osteosarcoma
Currently open trials in the same condition.
- NCT05691478 — A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma · Phase 2, PHASE3 · recruiting
- NCT04890067 — Observational Study in Localized Osteosarcoma · recruiting
Other Children's Oncology Group trials
Trials by the same sponsor.
- NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
- NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
- NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01190943 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
- Last refreshed: 28 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01190943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing